Evaluating Pharmaceuticals for Health Policy and Reimbursement

“The challenge in all settings is to make the difficult decisions in a way that is defensible, justifiable, ethical, and equitable”So write Nick Freemantle and Suzanne Hill in their introduction to this important discussion on decision making in the reimbursement of pharmaceuticals. Based around a programme supported by the World Health Organization, chapters by leading academics involved in the research tackle such major issues as international pharmaceutical policy, tensions in licensing policies, priority setting, and relationships between the stakeholders.Chapters includeDevelopment of marketing authorisation procedures for pharmaceuticalsInterpreting clinical evidenceInternational pharmaceutical policy: health creation or wealth creation?Development of fourth hurdle policies around the worldEconomic modelling in drug reimbursementPriority setting in health care: matching decision criteria with policy objectivesTensions in licensing and reimbursement decisions: case of riluzole for amytrophic lateral sclerosisRelationship between stakeholders: managing the war of wordsMedicine and the media: good information or misleading hype?How to promote quality use of cost-effective medicines Using economic evaluation to inform health policy and reimbursement: making it happen and making it sustainablePricing of pharmaceuticalsEvaluating pharmaceuticals for health policy in low and middle income country settings.Besides the controversial issues there is a wealth of practical information including economic modelling and the experiences from the WHO programme, providing readers with workable examples. This is essential reading for clinical researchers in pharmaceuticals and policy makers everywhere.Content: Chapter 1 Introduction (page 0): Nick Freemantle and Suzanne HillChapter 2 Development of Marketing Authorisation Procedures for Pharmaceuticals (pages 3–23): Alar Irs, Truus Janse de Hoog and Lembit RagoChapter 3 Interpreting Clinical Evidence (pages 24–45): Nick Freemantle, Joanne Eastaugh, Melanie Calvert, Suzanne Hill and Jesse BerlinChapter 4 International Pharmaceutical Policy: Health Creation or Wealth Creation? (pages 46–66): Karen Bloor and Alan MaynardChapter 5 Development of Fourth Hurdle Policies Around the World (pages 67–87): Rod S Taylor, Mike F Drummond, Glen Salkeld and Sean D SullivanChapter 6 Economic Modelling in Drug Reimbursement (pages 88–104): Glenn Salkeld, Nick Freemantle and Bernie O'BrienChapter 7 Priority Setting in Health Care:Matching Decision Criteria with Policy Objectives (pages 105–120): Gina Brinsmead and Alan WilliamsChapter 8 Tensions in Licensing and Reimbursement Decisions: The Case of Riluzole for Amytrophic Lateral Sclerosis (pages 121–138): Stirling Bryan, Josie Sandercock, Pelham Barton and Amanda BurlsChapter 9 Relationships Between Stakeholders: Managing the War of Words (pages 139–156): Suzanne Hill and Kees de JoncheereChapter 10 Medicine and the Media: Good Information or Misleading Hype? (pages 157–173): Moynihan Ray, Lisa M Schwartz and Steven WoloshinChapter 11 How to Promote Quality Use of Cost?Effective Medicines (pages 174–189): Hans Hogerzeil and Kathleen HollowayChapter 12 Using Economic Evaluation to Inform Health Policy and Reimbursement: Making it Happen and Making it Sustainable (pages 190–207): Andrew MitchellChapter 13 Pricing of Pharmaceuticals (pages 208–226): David Newby, Andrew Creese and Alan StevensChapter 14 Evaluating Pharmaceuticals for Health Policy in Low and Middle Income Country Settings (pages 227–243): Andrew Creese, Anita Kotwani, Joseph Kutzin and Anban Pillay